---
title: 'Imetelstat: A new addition to the Therapeutic Landscape of Lower-Risk MDS'
date: '2024-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39541576/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241115181608&v=2.18.0.post9+e462414
source: Blood
description: Anemia is the most prevalent cytopenia in lower-risk myelodysplastic
  neoplasms (LR-MDS). There is a paucity of drugs for red blood cell transfusion dependence
  (RBC-TD) and erythropoiesis-stimulating agents (ESAs) are the mainstay of therapy
  in many centers. Imetelstat, an oligonucleotide telomerase inhibitor, was recently
  approved for RBC-TD LR-MDS adults who are ineligible or failed prior ESA therapy.
  While not yet approved worldwide, here, we spotlight the current data for imetelstat
  and ...
disable_comments: true
---
Anemia is the most prevalent cytopenia in lower-risk myelodysplastic neoplasms (LR-MDS). There is a paucity of drugs for red blood cell transfusion dependence (RBC-TD) and erythropoiesis-stimulating agents (ESAs) are the mainstay of therapy in many centers. Imetelstat, an oligonucleotide telomerase inhibitor, was recently approved for RBC-TD LR-MDS adults who are ineligible or failed prior ESA therapy. While not yet approved worldwide, here, we spotlight the current data for imetelstat and ...